FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform.

• The FDA has approved the first mRNA-based flu vaccine, developed by Moderna, specifically for adults aged 50 and older. • Former FDA vaccine regulator Jesse Goodman noted the shot's documented superiority in effectiveness over standard doses for the 50-64 age group, particularly those with underlying health conditions.

• The author argues that modern medical science has shifted from seeking truth to protecting a "medical monopoly," leading to the suppression of effective therapies like chlorine dioxide. • The text criticizes the reliance on expensive randomized controlled trials (RCTs), claiming they are often manipulated by sponsors to artificially inflate the safety and efficacy of drugs.

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics.

• An FDA advisory panel has recommended the use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected the drug twice previously. • Rising oil prices driven by the conflict with Iran have sparked industry concerns regarding the vulnerability of essential medicine supply chains to price volatility.

• A new medical review suggests that reducing protein consumption may slow biological aging and extend lifespan by improving metabolism and lowering inflammation. • The research highlights that protein restriction preserves healthy cell function and reduces cellular damage, offering benefits similar to calorie restriction but without the need to limit total caloric intake.

• Gilead Sciences has successfully won a legal case regarding its HIV medication, securing a favorable ruling for the company. • Eli Lilly announced plans to expand patient access to retatrutide, a promising weight-loss and metabolic drug currently in development.

• The FDA has proposed a new hub-and-spoke manufacturing registration rule and approved three new drugs targeting bladder cancer, IgA nephropathy, and multiple myeloma. • A key industry trend highlighted is the shift from intravenous biologics to subcutaneous injectables to reduce patient infusion times and increase clinic capacity.

• Researcher Eric Verdin is studying experimental drugs, specifically GLP-1 medications, to determine if they can extend human life and mimic the benefits of calorie restriction. • While calorie restriction is known to improve lifespan and reduce age-related diseases, many individuals struggle to maintain the strict diets required to achieve these results.

• Two people in Michigan have died following a cyclospora outbreak, marking the first confirmed fatalities related to the microscopic parasite in the United States. • State health officials noted that while cyclosporiasis is rarely life-threatening, these deaths involved individuals with significant underlying health conditions.

• Pharmacy Times and the American College of Physicians have introduced new digital tools, including a dedicated iPad app for the internal medicine journal. • The Annals of Internal Medicine app provides practitioners with research, guidelines, and access to 12 months of archived journal issues.